Scoil Parent Company Winbond Technology Reports 90% Drop in Q1 2025 Net Profit, Revenue Falls 28% to 1.338 Billion Yuan

Apr.27.2025
Scoil Parent Company Winbond Technology Reports 90% Drop in Q1 2025 Net Profit, Revenue Falls 28% to 1.338 Billion Yuan
The report reveals a 28.29% year-on-year decline in operating revenue to 1.338 billion yuan (RMB), while net profit attributable to shareholders of the listed company plummeted 90.43% to 15.1642 million yuan. Notably, selling expenses surged 103.08% year-on-year, which the company attributes to intensified global market expansion efforts to bolster its international strategic footprint.

Recently, Shenzhen-based Yinghe Technology Co., Ltd. (300457.SZ) released its unaudited financial report for the first quarter of 2025. The report shows that the company's operating income decreased by 28.29% year-on-year to 1.338 billion RMB, and net profit attributable to shareholders of the listed company decreased by 90.43% to 15.1642 million RMB.

Scoil Parent Company Winbond Technology Reports 90% Drop in Q1 2025 Net Profit, Revenue Falls 28% to 1.338 Billion Yuan
2025 Q1 Financial Report | Image source: Yinghe Technology

 

Financial Highlights:

·Operating income: In the first quarter of 2025, the operating income reached 1.338 billion RMB, a decrease of 28.29% compared to 1.866 billion RMB in the same period last year. The company explained that the main reason for the decrease was that although market demand had increased and there were new orders, some orders had not yet been delivered, thus not contributing to revenue. 

·Net profit: The net profit attributable to shareholders of the listed company was 15.1642 million RMB, a significant decrease of 90.43% compared to 159 million RMB in the same period last year. The net profit after deducting non-recurring gains and losses was 12.6777 million RMB, a year-on-year decrease of 91.94%. The decrease in profit also led to a 60.65% decrease in income tax expenses. 

·Earnings per share: Both basic earnings per share and diluted earnings per share were 0.02 RMB, a 91.67% decrease compared to 0.24 RMB in the same period last year. 

·Total assets: As of the end of the reporting period, the company's total assets were 156.01 billion RMB, an increase of 5.69% compared to the end of the previous year.

 

Analysis of Key Changes

 

·Costs and Expenses: Operating costs decreased by 26.99% as revenue declined. Sales expenses increased by 103.08% year-on-year, mainly due to increased investment in expanding global markets to strengthen international strategic positioning. Research and development expenses increased by 41.11% year-on-year, due to increased investment in research and development to accelerate the launch of new products. 

 

·Items on the balance sheet: Accounts receivable and accounts receivable financing increased significantly, mainly due to good collection rates. Prepayments and short-term borrowings increased, mainly related to increased orders and meeting operational funding needs. Contract liabilities increased by 66.92%.

 

Scoil Parent Company Winbond Technology Reports 90% Drop in Q1 2025 Net Profit, Revenue Falls 28% to 1.338 Billion Yuan
Changes in the Profit and Loss Statement for Q1 2025 | Source: Yinghe Technology

 

Yinghe Technology is the controlling parent company of the e-cigarette company Shenzhen Sikary Technology Co., Ltd. (referred to as "Sikary"), holding a 51% stake. According to its 2024 annual report, the subsidiary Sikary had an annual operating income of approximately 3.191 billion yuan, operating profit of approximately 1.492 billion yuan, and a net profit of approximately 1.286 billion yuan.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU finance ministers failed to reach agreement on tobacco excise reform at the November 9, 2026 Economic and Financial Affairs Council (ECOFIN) meeting in Brussels. The Irish Council presidency's compromise secured support from 26 of the EU's 27 member states, but Malta withheld consent, preventing the Council from reaching a general approach requiring unanimity. The reform would raise minimum taxes on conventional tobacco and bring e-cigarette liquids, heated tobacco and nicotine pouches into a common EU minimum excise framework. Finland and Estonia accepted further concessions during the meeting, while the presidency proposed separating the inclusion of nicotine pouches in the framework from setting their precise minimum tax rates. Another compromise would allow ten qualifying member states until 2036 to meet certain tobacco excise requirements. Ireland intends to continue negotiations in December.
Regulations
Nov.11
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23